Michael David Clark's most recent trade in Amicus Therapeutics Inc was a trade of 221,811 Common Stock done at an average price of $14.5 . Disclosure was reported to the exchange on April 27, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Amicus Therapeutics Inc | David Michael Clark | Chief People Officer | Sale or transfer of securities back to the company at price $ 14.50 per share. | 27 Apr 2026 | 221,811 | 0 (0%) | 0% | 14.5 | 3,216,260 | Common Stock |
| Amicus Therapeutics Inc | David Michael Clark | Chief People Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Apr 2026 | 125,430 | 0 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | David Michael Clark | Chief People Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Apr 2026 | 108,266 | 0 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | David Michael Clark | Chief People Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Apr 2026 | 105,388 | 0 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | David Michael Clark | Chief People Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Apr 2026 | 91,439 | 0 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | David Michael Clark | Chief People Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Apr 2026 | 84,842 | 0 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | David Michael Clark | Chief People Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Apr 2026 | 83,221 | 0 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | David Michael Clark | Chief People Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Apr 2026 | 77,134 | 0 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | David Michael Clark | Chief People Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.27 per share. | 02 Jan 2026 | 18,498 | 221,811 (0%) | 0% | 14.3 | 263,966 | Common Stock |
| Amicus Therapeutics Inc | David Michael Clark | Chief People Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.27 per share. | 02 Jan 2026 | 5,381 | 240,309 (0%) | 0% | 14.3 | 76,787 | Common Stock |
| Amicus Therapeutics Inc | David Michael Clark | Chief People Officer | Sale of securities on an exchange or to another person at price $ 14.17 per share. | 19 Dec 2025 | 25,642 | 245,690 (0%) | 0% | 14.2 | 363,380 | Common Stock |
| Amicus Therapeutics Inc | David Michael Clark | Chief People Officer | Sale of securities on an exchange or to another person at price $ 11.00 per share. | 15 Dec 2025 | 25,643 | 271,332 (0%) | 0% | 11 | 282,073 | Common Stock |
| Amicus Therapeutics Inc | David Michael Clark | Chief People Officer | Sale of securities on an exchange or to another person at price $ 10.10 per share. | 24 Nov 2025 | 25,643 | 296,975 (0%) | 0% | 10.1 | 258,933 | Common Stock |
| Health In Tech Inc (Class A) | Michael David Clarkson | CISO | 05 Nov 2025 | 8,000 | 8,000 | - | 0 | Class A Common Stock | ||
| Amicus Therapeutics Inc | David Michael Clark | Chief People Officer | Sale of securities on an exchange or to another person at price $ 9.51 per share. | 04 Nov 2025 | 25,643 | 322,618 (0%) | 0% | 9.5 | 243,860 | Common Stock |
| Amicus Therapeutics Inc | David Michael Clark | Chief People Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2025 | 52,338 | 368,854 (0%) | 0% | 0 | Common Stock | |
| Amicus Therapeutics Inc | David Michael Clark | Chief People Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.57 per share. | 11 Feb 2025 | 20,593 | 348,261 (0%) | 0% | 9.6 | 197,075 | Common Stock |
| Amicus Therapeutics Inc | David Michael Clark | Chief People Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 125,430 | 125,430 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | David Michael Clark | Chief People Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 69,228 | 331,195 (0%) | 0% | 0 | Common Stock | |
| Amicus Therapeutics Inc | David Michael Clark | Chief People Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.41 per share. | 02 Jan 2025 | 11,987 | 319,208 (0%) | 0% | 9.4 | 112,798 | Common Stock |
| Amicus Therapeutics Inc | David Michael Clark | Chief People Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.31 per share. | 02 Jan 2025 | 5,381 | 261,967 (0%) | 0% | 9.3 | 50,097 | Common Stock |
| Amicus Therapeutics Inc | David Michael Clark | Chief People Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.41 per share. | 02 Jan 2025 | 2,692 | 316,516 (0%) | 0% | 9.4 | 25,332 | Common Stock |
| Amicus Therapeutics Inc | David Michael Clark | Chief People Officer | Sale of securities on an exchange or to another person at price $ 14.00 per share. | 15 Feb 2024 | 4,427 | 253,664 (0%) | 0% | 14 | 61,978 | Common Stock |
| Amicus Therapeutics Inc | David Michael Clark | Chief People Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2024 | 13,684 | 280,389 (0%) | 0% | 0 | Common Stock | |
| Amicus Therapeutics Inc | Michael David Clark | Chief People Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.65 per share. | 09 Jan 2024 | 8,614 | 258,091 (0%) | 0% | 13.6 | 117,581 | Common Stock |
| Amicus Therapeutics Inc | David Michael Clark | Chief People Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.65 per share. | 09 Jan 2024 | 8,614 | 271,775 (0%) | 0% | 13.6 | 117,581 | Common Stock |
| Amicus Therapeutics Inc | David Michael Clark | Chief People Officer | Sale of securities on an exchange or to another person at price $ 14.00 per share. | 08 Jan 2024 | 8,726 | 268,089 (0%) | 0% | 14 | 122,164 | Common Stock |
| Amicus Therapeutics Inc | Michael David Clark | Chief People Officer | Sale of securities on an exchange or to another person at price $ 14.00 per share. | 08 Jan 2024 | 1,384 | 266,705 (0%) | 0% | 14 | 19,376 | Common Stock |
| Amicus Therapeutics Inc | David Michael Clark | Chief People Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.44 per share. | 04 Jan 2024 | 2,692 | 276,815 (0%) | 0% | 13.4 | 36,180 | Common Stock |
| Amicus Therapeutics Inc | Clark David Michael | Chief People Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 83,221 | 83,221 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Clark David Michael | Chief People Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 48,209 | 297,488 (0%) | 0% | 0 | Common Stock | |
| Amicus Therapeutics Inc | Clark Michael David | Chief People Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.53 per share. | 02 Jan 2024 | 11,650 | 279,507 (0%) | 0% | 13.5 | 157,625 | Common Stock |
| Amicus Therapeutics Inc | Clark Michael David | Chief People Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.24 per share. | 02 Jan 2024 | 6,331 | 291,157 (0%) | 0% | 14.2 | 90,153 | Common Stock |
| Amicus Therapeutics Inc | Clark Michael David | Chief People Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2023 | 8,212 | 249,279 (0%) | 0% | 0 | Common Stock | |
| Amicus Therapeutics Inc | David Michael Clark | Chief People Officer | Sale of securities on an exchange or to another person at price $ 13.50 per share. | 18 Jan 2023 | 7,382 | 241,067 (0%) | 0% | 13.5 | 99,657 | Common Stock |
| Amicus Therapeutics Inc | David Michael Clark | Chief People Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jan 2023 | 47,621 | 267,187 (0%) | 0% | 0 | Common Stock | |
| Amicus Therapeutics Inc | David Michael Clark | Chief People Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.02 per share. | 11 Jan 2023 | 18,738 | 248,449 (0%) | 0% | 12.0 | 225,231 | Common Stock |
| Amicus Therapeutics Inc | David Michael Clark | Chief People Officer | Sale of securities on an exchange or to another person at price $ 11.87 per share. | 04 Jan 2023 | 21,507 | 219,566 (0%) | 0% | 11.9 | 255,346 | Common Stock |
| Amicus Therapeutics Inc | David Michael Clark | Chief People Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.03 per share. | 04 Jan 2023 | 2,692 | 241,073 (0%) | 0% | 12.0 | 32,385 | Common Stock |
| Amicus Therapeutics Inc | David Michael Clark | Chief People Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2023 | 105,388 | 105,388 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | David Michael Clark | Chief People Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2023 | 59,372 | 249,575 (0%) | 0% | 0 | Common Stock | |
| Amicus Therapeutics Inc | David Michael Clark | Chief People Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.21 per share. | 02 Jan 2023 | 11,336 | 198,696 (0%) | 0% | 12.2 | 138,413 | Common Stock |
| Amicus Therapeutics Inc | David Michael Clark | Chief People Officer | Sale of securities on an exchange or to another person at price $ 12.03 per share. | 02 Jan 2023 | 8,493 | 190,203 (0%) | 0% | 12.0 | 102,176 | Common Stock |
| Amicus Therapeutics Inc | David Michael Clark | Chief People Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.93 per share. | 02 Jan 2023 | 5,810 | 243,765 (0%) | 0% | 11.9 | 69,313 | Common Stock |
| Amicus Therapeutics Inc | David Michael Clark | Chief People Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.40 per share. | 09 Oct 2022 | 5,510 | 210,032 (0%) | 0% | 10.4 | 57,304 | Common Stock |
| Amicus Therapeutics Inc | David Michael Clark | Chief People Officer | Sale of securities on an exchange or to another person at price $ 12.50 per share. | 05 Aug 2022 | 11,322 | 215,542 (0%) | 0% | 12.5 | 141,525 | Common Stock |
| Amicus Therapeutics Inc | David Michael Clark | Chief People Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jan 2022 | 108,266 | 108,266 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | David Michael Clark | Chief People Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jan 2022 | 59,071 | 207,313 (0%) | 0% | - | Common Stock | |
| Amicus Therapeutics Inc | David Michael Clark | Chief People Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jan 2022 | 32,235 | 239,548 (0%) | 0% | - | Common Stock | |
| Amicus Therapeutics Inc | David Michael Clark | Chief People Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.53 per share. | 14 Jan 2022 | 12,684 | 226,864 (0%) | 0% | 10.5 | 133,563 | Common Stock |
| Amicus Therapeutics Inc | David Michael Clark | Chief People Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.51 per share. | 09 Oct 2021 | 5,510 | 168,879 (0%) | 0% | 11.5 | 63,420 | Common Stock |